Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clazosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB | P24530 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clazosentan SCHEMBL29706388 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1652657 | 1.00 | EDNRA (1.00) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4525 | 0.92 | EDNRA (1.00) | EDNRAEDNRB | |
| Tezosentan SCHEMBL29194446 | 0.91 | EDNRA (0.99) | EDNRAEDNRB | |
| Tezosentan SCHEMBL387773 | 0.91 | EDNRA (0.99) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29379450 | 0.88 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1983603 | 0.88 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581324 | 0.88 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581457 | 0.88 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974621 | 0.88 | EDNRA (0.78) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721742-A2 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Idorsia Pharmaceuticals Ltd (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-12534449-B2 | Stable crystalline hydrate of clazosentan disodium salt | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-01-27 | — | — | US | disclosed |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | UNIV EMORY (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4582086-A2 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20250051308-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-4448511-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Idorsia Pharmaceuticals Ltd (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20230373967-A1 | A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4240732-A1 | A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT | Idorsia Pharmaceuticals Ltd (CH) | 2023-09-13 | — | — | EP | disclosed |
| EP-4236961-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE | Emory University (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116685327-A | Orphan nuclear receptor modulators for the treatment of pancreatitis, glioblastoma, sarcopenia and stroke | 埃默里大学 | 2023-09-01 | — | — | CN | disclosed |
| CN-116456984-A | Stable crystalline hydrate of claritan disodium salt | 爱杜西亚药品有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023111299-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022096549-A1 | A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022094435-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE | EMORY UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051308-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SSTR5, SSTR3, TACR1 | EDNRA 203/4885EDNRB 320/4885 |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | RXRA, RXRG, RXRB | EDNRA 709/4885EDNRB 993/4885 |
| US-12534449-B2 | Stable crystalline hydrate of clazosentan disodium salt | EDNRA, AGTR2, AGTR1 | EDNRA 1/4885EDNRB 4/4885 |
| US-20230373967-A1 | A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT | SLC5A1, SLC10A1, SLC5A2 | EDNRA 595/4885EDNRB 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.